Skip to main content
. 2023 May 29;15(6):1269. doi: 10.3390/v15061269

Figure 2.

Figure 2

C1q (A) and C4BP (B) attenuate SARS-CoV-2 pseudoparticle entry into A549-hACE2+TMPRSS2 cells. Luciferase reporter activity of A549-hACE2+TMPRSS2 cells transduced with either treated or untreated SARS-CoV-2 lentiviral pseudoparticles pre-treated with C1q or C4BP (40 μmol/mL) was utilised to assess if the treatment by complement proteins interfered with the lentiviral pseudoparticles’ ability to enter the cells. The background was subtracted from all data points. The data obtained were normalised with 0% luciferase activity defined as the mean of the relative luminescence units recorded from the control sample (A549-hACE2+TMPRSS2 cells + SARS-CoV-2 lentiviral pseudoparticles). Pseudoparticles pre-treated with C1q and C4BP, blocked viral transduction. Data are shown as the normalized mean of three independent experiments carried out in triplicates ± SEM. Significance was determined using the two-way ANOVA test (*** p < 0.001) (n = 3).